Micafungina Hikma

Micafungin, the active ingredient in Micafungina Hikma, is a echinocandin presented as a injection for intravenous use. It treats invasive candidiasis, esophageal candidiasis, prophylaxis of Candida infections in hematopoietic stem cell transplant recipients, and Candida peritonitis and intra‑abdominal infections.

GNH USA supplies Micafungina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

- Invasive candidiasis: effective for bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves fungal infection of the esophagus. - Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during immunosuppression. - Candida peritonitis and intra‑abdominal infections: treats Candida‑related peritoneal and abdominal infections.

Micafungin may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Infusion‑related reactions such as flushing, chills, or rash. - Fever or chills during or after administration. - Nausea or mild gastrointestinal discomfort. - Elevated liver enzymes (ALT, AST). - Headache. - Mild hypotension.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Significant hepatic dysfunction or jaundice. - Acute renal impairment or increased creatinine. - Severe hypotension or shock. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Eosinophilic pneumonia.

Before initiating therapy, clinicians should assess organ function and potential risk factors. - Renal function: monitor serum creatinine and adjust therapy if impairment is detected. - Hepatic function: evaluate liver enzymes prior to and during treatment. - Pregnancy: category B; use only when the anticipated benefit justifies potential risk. - Drug interactions: review concomitant medications for possible pharmacokinetic interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungina Hikma may interact with several co‑administered drugs; monitoring is advised.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Tacrolimus: co‑administration can elevate tacrolimus levels. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin plasma concentrations. - Statins (e.g., simvastatin): potential for enhanced myopathy risk. - Warfarin: monitor INR as micafungin may affect anticoagulant control.